TSHA
NASDAQ
US
Taysha Gene Therapies, Inc. - Common Stock
$4.37
▲ +$0.06
(+1.39%)
Vol 1.6M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.5B
ROE
-67.3%
Margin
-1145.0%
D/E
23.44
Beta
1.09
52W
$1–$6
Wall Street Consensus
20 analysts · Apr 20266
Strong Buy
13
Buy
1
Hold
0
Sell
0
Strong Sell
95.0%
Buy Rating
Price Chart
Similar Stocks
PGEN
Precigen Inc
$1.5B
GLUE
Monte Rosa Therapeutics Inc
P/E 48.7
$1.0B
BCAX
Bicara Therapeutics Inc
$922.0M
OLMA
Olema Pharmaceuticals Inc
$2.0B
ZBIO
Zenas Biopharma Inc
$2.3B
NVAX
Novavax Inc
P/E 3.2
$1.1B
CRVS
Corvus Pharmaceuticals Inc
$575.1M
SVRA
Savara Inc
$1.2B
AVBP
ArriVent BioPharma Inc
$830.6M
GERN
Geron Corp
$842.6M
Earnings
Beat rate: 60.0%
Next Report
May 13, 2026
EPS Estimate: $-0.10
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.10 | — | — |
| Dec 2025 | $-0.10 | $-0.08 | +$0.02 |
| Sep 2025 | $-0.09 | $-0.09 | $0.00 |
| Jun 2025 | $-0.08 | $-0.09 | $-0.01 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -79.9% | -79.9% | -79.9% | -79.9% | -67.3% | -67.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -1353.6% | -1145.0% | -1145.0% | -1145.0% | -1145.0% | -1145.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 16.74 | 16.74 | 16.74 | 16.74 | 23.44 | 23.44 |
| Current Ratio | 12.48 | 12.48 | 12.48 | 12.48 | 10.48 | 10.48 |
Key Ratios
ROA (TTM)
-42.1%
P/S (TTM)
186.04
P/B
5.0
EPS (TTM)
$-0.33
CF/Share
$-2.76
52W High
$6.02
52W Low
$1.05
$1.05
52-Week Range
$6.02
How does TSHA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
TSHA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
186.0
▲
1348%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
5.0
▲
102%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
TSHA profitability vs Biotechnology peers
ROE
-67.3%
▲
0%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-1145.0%
▼
299%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-42.1%
▲
10%
above
peers
(-46.7%)
vs Peers
vs Industry
In line
TSHA financial health vs Biotechnology peers
D/E ratio
23.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
10.5
▲
136%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.1
▲
13%
above
peers
(1.0)
vs Peers
vs Industry
Less volatile
TSHA fundamentals radar
TSHA
Peer median
Industry
TSHA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio